These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 34544359)

  • 1. CGRP antibody therapy in patients with drug resistant migraine and chronic daily headache: a real-world experience.
    Scheffler A; Schenk H; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Holle D
    J Headache Pain; 2021 Sep; 22(1):111. PubMed ID: 34544359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Erenumab in highly therapy-refractory migraine patients: First German real-world evidence.
    Scheffler A; Messel O; Wurthmann S; Nsaka M; Kleinschnitz C; Glas M; Naegel S; Holle D
    J Headache Pain; 2020 Jul; 21(1):84. PubMed ID: 32620151
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Persistent effectiveness of CGRP antibody therapy in migraine and comorbid medication overuse or medication overuse headache - a retrospective real-world analysis.
    Scheffler A; Basten J; Menzel L; Binz D; Becker WA; Breunung V; Schenk H; Kleinschnitz C; Nsaka M; Lindner D; Holle D
    J Headache Pain; 2024 Jul; 25(1):109. PubMed ID: 38965463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of a reimbursement policy change on treatment with erenumab in migraine - a real-world experience from Germany.
    Hong JB; Lange KS; Fitzek M; Overeem LH; Triller P; Siebert A; Reuter U; Raffaelli B
    J Headache Pain; 2023 Oct; 24(1):144. PubMed ID: 37899428
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world evidence following a mandatory treatment break after a 1-year prophylactic treatment with calcitonin gene-related peptide (pathway) monoclonal antibodies.
    Nsaka M; Scheffler A; Wurthmann S; Schenk H; Kleinschnitz C; Glas M; Holle D
    Brain Behav; 2022 Jul; 12(7):e2662. PubMed ID: 35687795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antibody switch in non-responders to a CGRP receptor antibody treatment in migraine: A multi-center retrospective cohort study.
    Overeem LH; Peikert A; Hofacker MD; Kamm K; Ruscheweyh R; Gendolla A; Raffaelli B; Reuter U; Neeb L
    Cephalalgia; 2022 Apr; 42(4-5):291-301. PubMed ID: 34644203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A head-to-head observational cohort study on the efficacy and safety of monoclonal antibodies against calcitonin gene-related peptide for chronic and episodic migraine.
    Saccà F; Braca S; Sansone M; Miele A; Stornaiuolo A; De Simone R; Russo CV
    Headache; 2023 Jun; 63(6):788-794. PubMed ID: 37254581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and tolerability of eptinezumab in treating patients with migraine resistant to conventional preventive medications and CGRP (receptor) antibodies: a multicentre retrospective real-world analysis from Germany.
    Scheffler A; Wenzel P; Bendig M; Gendolla A; Basten J; Kleinschnitz C; Nsaka M; Lindner D; Naegel S; Burow P; Fleischmann R; Holle D
    J Headache Pain; 2024 May; 25(1):79. PubMed ID: 38755541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.
    Tepper SJ
    Headache; 2018 Nov; 58 Suppl 3():238-275. PubMed ID: 30242830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An observational study on monoclonal antibodies against calcitonin-gene-related peptide and its receptor.
    Schiano di Cola F; Bolchini M; Ceccardi G; Caratozzolo S; Liberini P; Rao R; Padovani A
    Eur J Neurol; 2023 Jun; 30(6):1764-1773. PubMed ID: 36856538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting response to CGRP-monoclonal antibodies in patients with migraine in Japan: a single-centre retrospective observational study.
    Ihara K; Ohtani S; Watanabe N; Takahashi N; Miyazaki N; Ishizuchi K; Hori S; Takemura R; Nakahara J; Takizawa T
    J Headache Pain; 2023 Mar; 24(1):23. PubMed ID: 36890436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overview on effectiveness of erenumab, fremanezumab, and galcanezumab in reducing medication overuse headache in chronic migraine patients.
    Curone M; Tullo V; Didier HA; Bussone G
    Neurol Sci; 2022 Sep; 43(9):5759-5761. PubMed ID: 35836032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of anti-CGRP monoclonal antibodies in resistant migraine patients: a real-world evidence observational study.
    Torres-Ferrús M; Gallardo VJ; Alpuente A; Caronna E; Gine-Cipres E; Pozo-Rosich P
    J Neurol; 2021 Oct; 268(10):3789-3798. PubMed ID: 33772636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resumption of migraine preventive treatment with CGRP(-receptor) antibodies after a 3-month drug holiday: a real-world experience.
    Raffaelli B; Terhart M; Mecklenburg J; Neeb L; Overeem LH; Siebert A; Steinicke M; Reuter U
    J Headache Pain; 2022 Mar; 23(1):40. PubMed ID: 35350990
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 100% Response Rate to Galcanezumab in Patients With Episodic Migraine: A Post Hoc Analysis of the Results From Phase 3, Randomized, Double-Blind, Placebo-Controlled EVOLVE-1 and EVOLVE-2 Studies.
    Rosen N; Pearlman E; Ruff D; Day K; Jim Nagy A
    Headache; 2018 Oct; 58(9):1347-1357. PubMed ID: 30341990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of three calcitonin gene-related peptide monoclonal antibodies for migraine: A 12-month, single-center, observational real-world study in Japan.
    Suzuki K; Suzuki S; Shiina T; Tatsumoto M; Fujita H; Haruyama Y; Hirata K
    Cephalalgia; 2023 May; 43(5):3331024231177649. PubMed ID: 37231663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early Effect of Calcitonin Gene-related Peptide Monoclonal Antibodies in Migraine with Medication Overuse: A Single-center Retrospective Study.
    Ito Y; Mitsufuji T; Okada M; Fujita S; Yokoyama R; Kawasaki H; Yamamoto T
    Intern Med; 2023 Dec; 62(23):3455-3460. PubMed ID: 37062749
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-world experience with calcitonin gene-related peptide-targeted antibodies for migraine prevention: a retrospective observational cohort study at two Japanese headache centers.
    Shibata M; Fujita K; Hoshino E; Minami K; Koizumi K; Okada S; Sakai F
    BMC Neurol; 2024 Jan; 24(1):32. PubMed ID: 38238659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world experience of erenumab in patients with chronic or episodic migraine in the UAE.
    Alsaadi T; Noori S; Varakian R; Youssef S; Almadani A
    BMC Neurol; 2022 Jun; 22(1):221. PubMed ID: 35710354
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pooled retrospective analysis of 70 mg erenumab in episodic and chronic migraine: a two tertiary headache centers experience during clinical practice.
    Storch P; Burow P; Möller B; Kraya T; Heintz S; Politz N; Naegel S
    Acta Neurol Belg; 2022 Aug; 122(4):931-937. PubMed ID: 34406609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.